For most people with bladder cancer, the first red flag is literally red: blood in the urine. But for people with color blindness, that warning sign may be easy to miss — and missing it could prove ...

Myasthenia gravis (MG) or its treatments may lead to urinary symptoms. Studies suggest a link between overactive bladder symptoms and a common MG medication called pyridostigmine. Urinary symptoms in ...

From as early as she can remember, Cindy O’Connor couldn’t control her bladder. She would suddenly feel the urge to pee and couldn’t make it to the bathroom before urine leaked out. In kindergarten, ...

Adenocarcinoma of the bladder is rare, originating from glandular cells, and can be primary or secondary, requiring accurate diagnosis for appropriate treatment. Diagnosis involves cystoscopy, biopsy, ...

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...

Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...

It wasn’t the ending we hoped for. The sadness was palpable in The Stranger’s Capitol Hill offices the day after the Toronto Blue Jays shattered the Seattle Mariners’ dreams of finally making it to ...

An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

From the Uresta Starter Kit, a woman selects one of the bladder support device sizes to find her best fit for comfort and effectiveness. A femtech startup is bringing a non-surgical solution for women ...

Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...